| Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice. | |
| | |
MedLine Citation:
|
PMID: 22852029 Owner: NLM Status: PubMed-not-MEDLINE |
Abstract/OtherAbstract:
|
Clinical stage I testicular nonseminomatous germ cell tumours (NSGCTs) are highly curable. Following orchidectomy a risk-adapted approach using active surveillance (AS), nerve-sparing retroperitoneal lymph node dissection (nsRPLND) and primary chemotherapy is recommended by the current guidelines. Clinical stage I is defined as negative or declining tumour markers to their half-life following orchidectomy and negative imaging studies of the chest, abdomen and retroperitoneum. Active surveillance can be performed in low-risk and in high-risk NSGCTs with an anticipated relapse rate of about 15% and 50%. The majority of patients will relapse with good and intermediate prognosis tumours which have to be treated with three to four cycles chemotherapy. About 25-30% of these patients will have to undergo postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for residual masses. Primary chemotherapy with one or two cycles of cisplatin (Platinol), etoposide and bleomycin (PEB) is a therapeutic option for high-risk clinical stage I NSGCT associated with a recurrence rate of only 2-3% and a minimal acute and long-term toxicity rate. nsRPLND, if performed properly, will cure about 85% of all high-risk patients with clinical stage I NSGCT without the need for chemotherapy. PC-RPLND forms an integral part of the multimodality treatment in patients with advanced testicular germ cell tumours (TGCTs). According to current guidelines and recommendations, PC-RPLND in advanced seminomas with residual tumours is only indicated if a positron emission tomography (PET) scan performed 6-8 weeks after chemotherapy is positive. In nonseminomatous TGCT, PC-RPLND is indicated for all residual radiographic lesions with negative or plateauing markers. Loss of antegrade ejaculation represents the most common long-term complication which can be prevented by a nerve-sparing or modified template resection. The relapse rate after PC-RPLND is around 12%, however it increases significantly to about 45% in cases with redo RPLND and late relapses. Patients with increasing markers should undergo salvage chemotherapy. Only select patients with elevated markers who are thought to be chemorefractory might undergo desperation PC-RPLND if all radiographically visible lesions are completely resectable. PC-RPLND requires a complex surgical approach and should be performed in experienced, tertiary referral centres only. |
| | |
Authors:
|
Axel Heidenreich; David Pfister |
Related Documents
:
|
22740329 - Relationship between histopathology of pleomorphic adenoma in the parotid gland and rec... 22572079 - Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiosurgery. 22438359 - Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. 22300609 - Prognostic significance of the total dose of cisplatin administered during concurrent c... 1884559 - Management of osteogenic sarcoma in children and adolescents. 7595829 - Malignant solid tumors in neonates: a 40-year review. 18362479 - Ta t1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates... 19782419 - A randomized phase ii study of ceop with or without semustine as induction chemotherapy... 22740329 - Relationship between histopathology of pleomorphic adenoma in the parotid gland and rec... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Therapeutic advances in urology Volume: 4 ISSN: 1756-2880 ISO Abbreviation: Ther Adv Urol Publication Date: 2012 Aug |
Date Detail:
|
Created Date: 2012-08-01 Completed Date: 2012-08-23 Revised Date: 2013-03-05 |
Medline Journal Info:
|
Nlm Unique ID: 101487328 Medline TA: Ther Adv Urol Country: England |
Other Details:
|
Languages: eng Pagination: 187-205 Citation Subset: - |
Affiliation:
|
Director and Chairman, EURO Prostate Center, Department of Urology, Urologic Oncology, Pediatric Urology and Renal Transplantation, RWTH University Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sacral neuromodulation and refractory overactive bladder: an emerging tool for an old problem.
Next Document: Biological reconstruction of bone defects: the role of the free fibula flap.